KROS (Keros Therapeutics) EBITDA Margin %: -6,941.14% (As of Mar. 2026)


KROS Keros Therapeutics Inc KROS
30 GF Score
Price $10.92
! 3 Warning Signs
View Full Analysis

What is Keros Therapeutics EBITDA Margin %?

Keros Therapeutics KROS -0.55% 30 EBITDA Margin % is -6,941.14% as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Keros Therapeutics ranks worse than 67.41% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Keros Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-25.47 Mil. Keros Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.37 Mil. Therefore, Keros Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -6,941.14%.

Keros Therapeutics  (NAS:KROS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Keros Therapeutics EBITDA Margin % Related Terms

Keros Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics EBITDA Margin % Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -280.35 0.00 -100,779.47 -5,869.46 28.30

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.14 -217.12 -105.10 -7,498.70 -6,941.14

KROS vs RNA, RNAC, ARCT: EBITDA Margin % Comparison

For the Biotechnology subindustry, Keros Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's EBITDA Margin % falls into.


KROS
30GF Score
Keros Therapeutics Inc KROS
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Keros Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=69.078/244.061
=28.30 %

Keros Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-25.474/0.367
=-6,941.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -6,941.14% mean?
Keros Therapeutics (KROS) has a EBITDA Margin % of -6,941.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #637 out of 945 companies in the Biotechnology industry, placing it in the top 67.4%.
Is Keros Therapeutics' EBITDA Margin % too high?
Keros Therapeutics' current EBITDA Margin % is -6,941.14%. Based on the distribution chart, Keros Therapeutics ranks #637 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' EBITDA Margin % compare to RNA and RNAC?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #637 out of 945 companies for EBITDA Margin %. This places Keros Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current EBITDA Margin % is -6,941.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current EBITDA Margin % of -6,941.14%. The current EBITDA Margin % is -6,941.14%. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current EBITDA Margin % is -6,941.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.92
Price